FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Spironolactone

Drug and asset intelligence for Spironolactone with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Annora Pharma →

Recent signals(2)

StrategyJuly 15, 2026

FDA Grants AP Status for Spironolactone ANDA203512 by Accord Healthcare

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Spironolactone submitted by Accord Healthcare.

StrategyJuly 15, 2026

FDA Grants AP Status for Spironolactone ANDA217761 by Annora Pharma

The FDA has granted Abbreviated Approval (AP) status for Annora Pharma's ANDA217761 for spironolactone.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

— Spironolactone

July 15, 2026 · N/A

Topline Data

— Spironolactone

July 15, 2026 · N/A

Topline Data

— Spironolactone

July 15, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Cardiology →

Cardiology · Diuretic →

Diuretic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.